Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that it has recently received clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease. The Company plans to initiate the clinical trial in the near term.
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the New Drug Application (NDA) for AP301 capsules, a novel oral iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving maintenance dialysis, is formally accepted for review by China's National Medical Products Administration (NMPA) today. The NDA is supported primarily by the resul
Recently published Hyperphosphatemia Market Insights report includes a comprehensive understanding of current treatment practices, hyperphosphatemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dosed in the global Phase IIb multi-regional clinical trial of AP306 in patients with hyperphosphatemia receiving maintenance hemodialysis (NCT06712654). The trial is being conducted at multiple clinical sites in the United States and China and is co-sponsored by Alebund and R1 Therapeutics, Inc. ("R1").
Alebund Pharmaceuticals (Jiangsu) (SEHK:9637) has just completed an IPO raising about HK$1.283b through H share offerings priced at HK$22.6, giving investors fresh access to this kidney disease focused biopharmaceutical stock. See our latest analysis for Alebund Pharmaceuticals (Jiangsu). Since listing, Alebund Pharmaceuticals (Jiangsu) has moved from its HK$22.60 offer price to a latest share price of HK$29.18, but the 7 day share price return of about 36% and year to date share price return...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.